Sino Biopharmaceutical (HKG:1177) said the phase III trial of TQB3454 developed by unit Chia Tai Tianqing Pharmaceutical Group reached the pre-specified primary endpoints of both progression-free and overall survival, according to a Thursday Hong Kong bourse filing.
The drug is being tested for the treatment of advanced biliary tract cancer with IDH1 mutations.
The pharmaceutical firm has communicated with China's National Medical Products Administration in relation to the marketing application for this indication and obtained written approval. The marketing application will be submitted soon.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments